An investor relations event hosted by the province of Gangwon was held at its community hall located in Mapo District, western Seoul on Tuesday. Around 100 people including Gangwon Governor Kim Jin-tae attended the event.
JW1601, an oral atopy treatment candidate that was licensed by JW Pharmaceutical to Ballerup, Denmark-based Leo Pharma began Phase 2 clinical trials, the Korean company said Wednesday.
GC Pharma won a $48.9 million flu vaccine deal with the Pan American Health Organization (PAHO), the company said Monday.
Korean biopharmaceutical companies are enjoying a strong third quarter on the lingering Covid-19 pandemic and sales of vaccines they produce under contract manufacturing organization (CMO) deals.
GNT Pharma's stroke treatment candidate Nelonemdaz won approval to start Phase 3 clinical trials in Korea, the company said Tuesday.
GC Pharma signed a partnership agreement with Austin, Texas-based Speragen for joint development of a treatment for succinic semialdehyde dehydrogenase deficiency (Ssadhd), the company said Tuesday.
After reviewing GC Pharma's clinical trial data, a committee under the Ministry of Food and Drug Safety recommended regulators not grant conditional use approval, saying the trial results were insufficient to prove the drug's safety and efficacy.
The Ministry of Food and Drug Safety said Friday that GC Pharma submitted paperwork to start the approval process for GC5131A. If conditional use is approved, GC5131A will be the second Korea-made Covid-19 treatment to get a nod.
Three more Korea-made Covid-19 treatments are trying to get conditional use approval this year. Vaccines are a different story and companies' progress so far suggests Korea-developed jabs are unlikely to reach the market this year.
GC Pharma completed injections for Phase 2 clinical trials of its Covid-19 treatment candidate in late December, the company confirmed Wednesday.
Korea JoongAng Daily Sitemap